Media headlines about Pharmerica Corporation (NYSE:PMC) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pharmerica Corporation earned a news impact score of 0.06 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.8112350558825 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

A number of equities research analysts recently commented on the company. Barrington Research cut Pharmerica Corporation from an “outperform” rating to an “underperform” rating in a research note on Wednesday, August 9th. KeyCorp cut Pharmerica Corporation to an “overweight” rating in a research note on Tuesday, August 8th. Zacks Investment Research raised Pharmerica Corporation from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research note on Wednesday, September 27th. UBS AG reaffirmed a “neutral” rating and set a $29.25 price objective (up from $26.00) on shares of Pharmerica Corporation in a research note on Thursday, August 3rd. Finally, BidaskClub cut Pharmerica Corporation from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Two analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company. Pharmerica Corporation presently has an average rating of “Hold” and an average target price of $30.50.

Shares of Pharmerica Corporation (NYSE:PMC) opened at 29.20 on Wednesday. The company’s 50 day moving average price is $29.15 and its 200-day moving average price is $26.46. The firm has a market capitalization of $908.73 million, a PE ratio of 39.57 and a beta of 0.84. Pharmerica Corporation has a 52 week low of $19.20 and a 52 week high of $29.50.

Pharmerica Corporation (NYSE:PMC) last posted its quarterly earnings data on Wednesday, August 2nd. The company reported $0.47 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.47. The business had revenue of $592.00 million during the quarter, compared to the consensus estimate of $592.96 million. Pharmerica Corporation had a return on equity of 10.94% and a net margin of 1.05%. Pharmerica Corporation’s quarterly revenue was up 13.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.47 earnings per share. On average, equities research analysts expect that Pharmerica Corporation will post $1.94 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Pharmerica Corporation (PMC) Receiving Somewhat Favorable News Coverage, Report Shows” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/18/pharmerica-corporation-pmc-receiving-somewhat-favorable-news-coverage-report-shows.html.

Pharmerica Corporation Company Profile

Insider Buying and Selling by Quarter for Pharmerica Corporation (NYSE:PMC)

Receive News & Stock Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related stocks with our FREE daily email newsletter.